New paper from Pope Woodhead evaluates the potential of digital to drive real patient-centered models

Advanced digital tools promise a smarter, more patient-centric healthcare model in which patients’ data informs developments and outcomes. But can this promise become reality? The signs are encouraging: pharmaceutical companies may have traditionally been behind the curve when it came to adopting digital technologies, but they are increasingly embracing digital platforms.

Read more ...

Many organisations consider setting up Centres of Excellence to help to develop new capabilities or enhance existing ones. This task can sometime be a challenge due to internal resistance to the idea or previous experienced of these kind of functions turning into ‘ivory towers’ producing ideas and concepts that the organisation can’t understand and doesn’t want to use. In this podcast the global Head of Marketing and Launch excellence shares his experiences of how to make a Centre of Excellence model a success.

Read more ...

A refined approach to orphan drug development is central to meeting patients’ needs

Achieving the optimum balance between accessibility and risk is vital for any drug development, but particularly so in the case of rare diseases, where unmet needs are acute and existing treatments often limited. And yet an imbalance persists, with too few orphan treatments reaching patients via traditional regulatory and access routes. Addressing this, regulators and HTA bodies/payers are looking to accelerate development and early access pathways for orphan drugs, with PRIME and other initiatives encouraging greater innovation around access and time to market.

Read more ...

CHMP Chair discusses expectations and challenges for the future

For PRIME co-founder and spokesperson Tomas Salmonson, finding more efficient and ‘joined-up’ ways of developing medicines that treat unmet medical needs is fundamental to the successful future of advanced healthcare. Today, too few products reach their clinical potential, reflecting complex markets, changing legislation and wide differences in the influence of stakeholders.

Read more ...

It’s almost impossible to name a country where healthcare budgets are not stretched. Whilst the attention of media, governments and regulators is often focused on new and innovative medicines, some countries are looking to save money by reducing the spend on generic drugs. In this double-issue article, Pope Woodhead draws on case studies from Canada and Australia to highlight the potential for reducing such costs, with the benefit of redirecting monies to meet other health needs.

Read more ...

More Articles ...

Receive Our Newsletter

Please fill out the form below to receive our newsletter. Alternatively email